Lantheus Holdings (LNTH) Cash from Investing Activities (2014 - 2026)
Lantheus Holdings (LNTH) posted quarterly Cash from Investing Activities of $26.0 million for Q1 2026, up 140.78% year-over-year from $10.8 million in Q1 2025, and up 325.77% quarter-over-quarter from -$11.5 million in Q4 2025.
Lantheus Holdings (LNTH) Cash from Investing Activities (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has reported Cash from Investing Activities for 13 consecutive years, with $26.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Investing Activities rose 140.78% year-over-year to $26.0 million; the TTM figure through Mar 2026 stood at -$537.5 million (down 193.37% YoY), while the FY2025 annual figure was -$627.2 million, down 177.49% from the prior year.
- Cash from Investing Activities improved to $26.0 million in Q1 2026 per LNTH's latest filing, from -$11.5 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $83.2 million in Q3 2023 and bottomed at -$319.5 million in Q3 2025.
- Historically, Cash from Investing Activities has averaged -$64.6 million across 5 years, with a median of -$20.7 million in 2023.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities slumped 5725.79% — and 2023, when it jumped 1466.47%.
- Lantheus Holdings' Cash from Investing Activities stood at -$264.7 million in 2022, then jumped by 95.44% to -$12.1 million in 2023, then jumped by 45.3% to -$6.6 million in 2024, then plunged by 74.34% to -$11.5 million in 2025, then surged by 325.77% to $26.0 million in 2026.
- Business Quant data shows LNTH's Cash from Investing Activities at $26.0 million in Q1 2026, -$11.5 million in Q4 2025, and -$319.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Lantheus Holdings | 6.52 Bn | 5.93 Bn | 241.86 Mn | -2.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.02 Mn |
| Jun 30, 2026 | -2.02 Mn |
| Mar 31, 2026 | 25.99 Mn |
| Mar 31, 2026 | 25.99 Mn |
| Dec 31, 2025 | -11.51 Mn |
| Dec 31, 2025 | -11.51 Mn |
| Sep 30, 2025 | -319.47 Mn |
| Sep 30, 2025 | -319.47 Mn |
| Jun 30, 2025 | -232.47 Mn |
| Jun 30, 2025 | -232.47 Mn |
| Mar 31, 2025 | -63.72 Mn |
| Mar 31, 2025 | -63.72 Mn |
| Dec 31, 2024 | -6.60 Mn |
| Dec 31, 2024 | -6.60 Mn |
| Sep 30, 2024 | -67.80 Mn |
| Sep 30, 2024 | -67.80 Mn |
| Jun 30, 2024 | -45.09 Mn |
| Jun 30, 2024 | -45.09 Mn |
| Mar 31, 2024 | -106.53 Mn |
| Mar 31, 2024 | -106.53 Mn |